Learn how Johnson and Johnson proactively reacted to COVID-19.

On January 11th, 2020 the first death was linked to 2019-nCoV. The very next day J&J initiates efforts to develop a vaccine candidate against 2019-nCoV, as well as collaborating with others to screen libraries full of antiviral molecules. A month later after it was announced an international threat, J&J began collaboration with the US Department of Health to accelerate the production of a vaccine, and expanded this collaboration as the virus spread internationally. 

Two weeks after being declared a pandemic, J& announced a 50 million commitment to support front line health workers. A few days later, J&J announces a lead vaccine candidate and will move into trials, pledging to supply $1 Billion vaccines worldwide and partnering with BARDA committing $1B to vaccine R&D. As of June, J&J has announced that phase 1/2a of the clinical trial will begin in the second half of July. J&J continues to stay devoted to helping find solutions to COVID-19 and in the meantime minimizing the suffering and loss of life occurring.